argenx Announces European Commission Approval of
VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe argenx is committed to continued collaboration...
Source: globenewswire.com
Anant Murthy News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Anant Murthy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Anant Murthy Today - Breaking & Trending Today
argenx Announces Positive CHMP Opinion for Subcutaneous
Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered...
Source: globenewswire.com
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis - argenx (NASDAQ:ARGX)
Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigimod, compared to intravenous (IV) administrationEuropean
Source: benzinga.com
Avanzanite Bioscience Launches Novel Business Model to Commercialize Innovative Medicines for Rare Diseases in Europe
Establishes first-in-class biopharmaceutical commercialization platform specifically addressing rare diseases in Europe Secured exclusive rights in 26 European Countries to an investigational
Source: finanznachrichten.de
Biopharma Looks to the Netherlands as European Hub
In the fall of 2016, Alnylam Pharmaceuticals was looking to expand. The Cambridge, Massachusetts–based company had therapies based on RNA interference (RNAi) technology in late-stage clinical testing for a handful of rare diseases, and wanted to establish a presence in Europe to better serve patients there. By the end of the following year, the company had opened offices in Maidenhead, UK; Zug, Switzerland; and Amsterdam, the Netherlands, to serve as its three European hubs. Scouting for new locations in Europe, the company found Amsterdam particularly appealing, says Marco Fossatelli, Alny...
Source: the-scientist.com